(Q35873832)

10 August 2017

1 reference

title

Review article: prognosis of hepatorenal syndrome--has it changed with current practice? (English)

1 reference

10 August 2017

1 reference

Angeli P

1

1 reference

PubMed ID

15335400

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Alimentary Pharmacology & Therapeutics

10 August 2017

1 reference

10 August 2017

20 Suppl 3

1 reference

10 August 2017

44-6; discussion 47-8

1 reference

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

The North American Study for the Treatment of Refractory Ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02113.X

10.1111/J.1365-2036.2004.02113.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15335400